The FDA clears Hologic’s femur fracture diagnostic exam, a 15-second test that will roll out as part of the company’s Horizon DXA platform.

Hologic (NSDQ:HOLX) touted a new FDA clearance for its Single Energy Femur Exam, a test for finding rare, unusual femur fractures that pose a high risk to patients. The diagnostic exam is intended for patients that do not respond to bisphosphonates, drugs prescribed to prevent osteoporosis.

Researchers have flagged a correlation between long-term use of bisphosphonates and these potentially deadly atypical femur fractures, the company said. Hologic’s femur exam is a 15-second test available through the company’s Horizon DXA imaging platform.